Edition:
United Kingdom

Akcea Therapeutics Inc (AKCA.OQ)

AKCA.OQ on NASDAQ Stock Exchange Global Select Market

21.37USD
23 May 2019
Change (% chg)

-- (--)
Prev Close
$21.37
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
81,990
52-wk High
$40.60
52-wk Low
$19.70

About

Akcea Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing drugs to treat patients with serious cardiometabolic diseases caused by lipid disorders. The Company's drugs, volanesorsen, AKCEA-APO(a)-LRx, AKCEA-ANGPTL3-LRx and AKCEA-APOCIII-LRx, are all based on antisense... (more)

Overall

Beta: --
Market Cap(Mil.): $1,982.50
Shares Outstanding(Mil.): 92.77
Dividend: --
Yield (%): --

Financials

  AKCA.OQ Industry Sector
P/E (TTM): -- 31.06 35.62
EPS (TTM): -1.88 -- --
ROI: -60.38 11.99 11.69
ROE: -63.16 13.29 16.40

EU committee approves Akcea-Ionis drug for rare genetic disease

March 1 An advisory committee of the European Medicines Agency (EMA) on Friday recommended conditionally approving a drug from Akcea Therapeutics Inc and Ionis Pharmaceuticals Inc that aims to treat a rare genetic disease that causes fat accumulation in the blood.

01 Mar 2019

Novartis aims to pump up cardio business with Ionis deal

ZURICH Novartis will pay $150 million to Ionis Pharmaceuticals to license an RNA-targeting cardiovascular drug as the Swiss company aims to bolster its range of heart disease treatments that now includes the blockbuster Entresto.

25 Feb 2019

UPDATE 2-Novartis aims to pump up cardio business with Ionis deal

* Novartis aims to build up heart drug portfolio (Adds comment from Novartis drug developer, details of payment and deal)

25 Feb 2019

BRIEF-Akcea Therapeutics Says Co Will Receive A $150 Mln License Fee That Will Be Split Equally With Ionis

* AKCEA-APO(A)-LRX ADVANCES AS LEADING PHARMACEUTICAL COMPANY EXERCISES OPTION TO LICENSE

25 Feb 2019

Earnings vs. Estimates